ClinicalTrials.Veeva

Menu

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Amicus Therapeutics logo

Amicus Therapeutics

Status

Completed

Conditions

Epidermolysis Bullosa

Treatments

Other: Survey

Study type

Observational

Funder types

Industry

Identifiers

NCT03158662
EB Survery 2017

Details and patient eligibility

About

This survey intends to collect information on key aspects of life with epidermolysis bullosa (EB), including diagnostic journey, treatment, management, daily living challenges, and overall psycho-social, socio-economic, academic and family impact.

Objectives:

  • To understand the unmet needs for people living with EB in the US
  • To assess the differences/similarities in the management/treatment of EB patients (including wound care, symptom management and other issues)
  • To assess the EB patients' and caregivers' perceptions of current management/treatment
  • To assess the challenges and the burden of daily living with EB
  • To understand EB diagnostic journey (the time to diagnosis and by what type of healthcare provider)
  • To identify professional disciplines involved in the diagnosis and management of EB
  • To understand the psycho-social, socio-economic, academic, and family impact of EB

Full description

Epidermolysis bullosa (EB) is a rare, often severe genetic disorder characterized by mechanical fragility and blistering or erosion of the skin, mucosa, or epithelial lining of other organs, in response to little or no apparent trauma.

EB is chronic, potentially disfiguring, and in some cases fatal. Patients with EB have painful wounds and blisters that can lead to infection and scarring. There are many genetic and symptomatic variations of EB, but all forms share the common symptom of fragile skin that blisters and tears, sometimes from the slightest friction or trauma. There is currently no approved treatment for EB. Current standard of care consists of pain management and the bandaging and cleaning of open wounds to prevent infection.

While there are a number of publications/guidance/consensus statements related to the diagnosis and management of EB from the point of view of the health-care provider/disease expert, there is a need for more research to define the key aspects of life with EB (i.e. diagnostic journey, treatment, management, daily living challenges, and overall disease burden) from the perspective of the patient.

Enrollment

150 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Confirmed diagnosis of EB including subtype
  • Resident of the US
  • Informed Consent
  • Patient must be 18 years or older
  • If the survey is done by a caregiver, they must be a parent or legal guardian and must be 18 years or older to answer on behalf of a patient under 18 years or on behalf of a patient 18 years or older who is unable to answer for themselves.
  • Must participate in and complete a one hour telephone interview

Exclusion criteria

  • Patient failing to meet the inclusion criteria above

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems